"Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year 2026."
Ann: Immutep receives Australian R&D Tax Incentive, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $584.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.0¢ | 40.0¢ | $833.9K | 2.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 38358 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 105000 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
41.5¢ |
Change
0.000 ( 3.29 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 42.0¢ | 40.5¢ | 804683 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| IMM (ASX) Chart |